今, 高之 ,
山路, 健 ,
Takayuki, Kon ,
Ken, Yamaji ,
Department of Rheumatology and Internal Medicine, Juntendo University School of MedicineDepartment of Rheumatology and Internal Medicine, Juntendo University School of Medicine
日本アフェレシス学会雑誌 = Japanese journal of apheresis
113 , 2015-05-31
Classification of vasculitis from CHCC (Chapel Hill Consensus Conference) 1994 was revised in 2012 based on its pathology and etiology. The presence of biologic agents changed treatment strategy for the category of autoimmune diseases, but this change is not applicable for every case because of economic problems and adverse effects of the agents. We must understand the mechanism of the each vasculitis case because apheresis treatment for vasculitis syndrome has only limited evidence. Therefore, the role of apheresis is significant as supportive or alternative therapy for vasculitis syndrome in the era of the biologic agents.